CD40LG and clostridium difficile infection: Finally, in light of recent antibody-based therapy research which has been stimulated by SARS-CoV-2 and which has been met with some success [43,44,45,46,47], consideration should also be given to the development and testing of IgM-enriched IVIg preparations or the utilisation of hyperimmune IVIg to provide standardised and controlled antibody content from patients that have recovered from CDI who have anti-toxin neutralising antibodies in their plasma.